Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M1 positive allosteric modulator VU0467319 for Alzheimer’s disease: a single ascending-dose study in healthy participants

Abstract The development of cholinergic neurotransmitter based cognitive enhancers for Alzheimer’s disease and other neuropsychiatric disorders have focused recently on allosteric modulation of specific muscarinic acetylcholine receptor (mAChR) subtypes to reduce dose-limiting side-effects that have...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Alexander C. Conley, Alexandra P. Key, Jennifer U. Blackford, Jason K. Russell, Kimberly M. Albert, Xuewen Gong, Michael Bubser, Jerri M. Rook, P. Jeffrey Conn, Craig W. Lindsley, Carrie K. Jones, Paul A. Newhouse
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2025-07-01
coleção:	Alzheimer’s Research & Therapy
Assuntos:	Muscarinic acetylcholine receptor subtype 1 (M1) Positive allosteric modulator (PAM) Cognition Metabolism Pharmacokinetics Pharmacodynamics
Acesso em linha:	https://doi.org/10.1186/s13195-025-01798-4
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!